Serum YKL-40 and colorectal cancer
Summary YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1999-03, Vol.79 (9), p.1494-1499 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1499 |
|---|---|
| container_issue | 9 |
| container_start_page | 1494 |
| container_title | British journal of cancer |
| container_volume | 79 |
| creator | Cintin, C Johansen, J S Christensen, I J Price, P A Sørensen, S Nielsen, H J |
| description | Summary
YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes’ A, 26% with Dukes’ B, 19% with Dukes’ C and 39% with Dukes’ D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (
P
< 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1,
P
< 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes’ stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8,
P
= 0.007). These results suggest that YKL-40 may play an important role in tumour invasion. |
| doi_str_mv | 10.1038/sj.bjc.6690238 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69663001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-af13007aff61bcc4436320179090c3b00fcdd87bcbfe003a34e158fa5ffac953</originalsourceid><addsrcrecordid>eNp1kM1LwzAYh4Mobk6vHmWIeGv3pmnS9CLI8AsHHtzFU0jTZLb0Yyat4H9vRovOg6cQ3uf9_V4ehM4xhBgIX7gyzEoVMpZCRPgBmmJKogDzKDlEUwBIAkgjmKAT50r_TYEnx2iCAXPOUzZFl6_a9vX87XkVxDCXTT5XbdVarTpZzZVslLan6MjIyumz8Z2h9f3devkYrF4enpa3q0DFlHaBNJj4PmkMw5lScUwYiQAnqS9VJAMwKs95kqnMaAAiSawx5UZSY6RKKZmhmyF222e1zpVuOisrsbVFLe2XaGUh_k6a4l1s2k8RERYlEfiA6zHAth-9dp2oC6d0VclGt70TLGXMX4g9GA6gsq1zVpufEgxiZ1W4UnirYrTqFy72T9vDB40euBoB6ZSsjPXiCvfLJZRhusMWA-b8pNloK8q2t42X-l_zN54Xj5I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69663001</pqid></control><display><type>article</type><title>Serum YKL-40 and colorectal cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Cintin, C ; Johansen, J S ; Christensen, I J ; Price, P A ; Sørensen, S ; Nielsen, H J</creator><creatorcontrib>Cintin, C ; Johansen, J S ; Christensen, I J ; Price, P A ; Sørensen, S ; Nielsen, H J</creatorcontrib><description>Summary
YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes’ A, 26% with Dukes’ B, 19% with Dukes’ C and 39% with Dukes’ D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (
P
< 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1,
P
< 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes’ stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8,
P
= 0.007). These results suggest that YKL-40 may play an important role in tumour invasion.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/sj.bjc.6690238</identifier><identifier>PMID: 10188896</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adipokines ; Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoembryonic Antigen - blood ; Case-Control Studies ; Chitinase-3-Like Protein 1 ; Colonic Neoplasms - blood ; Colonic Neoplasms - mortality ; Colonic Neoplasms - pathology ; Drug Resistance ; Epidemiology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Glycoproteins - blood ; Humans ; Lectins ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Neoplasm Staging ; Oncology ; Rectal Neoplasms - blood ; Rectal Neoplasms - mortality ; Rectal Neoplasms - pathology ; Regular ; regular-article ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Analysis ; Tumors</subject><ispartof>British journal of cancer, 1999-03, Vol.79 (9), p.1494-1499</ispartof><rights>The Author(s) 1999</rights><rights>1999 INIST-CNRS</rights><rights>Copyright © 1999 Cancer Research Campaign 1999 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-af13007aff61bcc4436320179090c3b00fcdd87bcbfe003a34e158fa5ffac953</citedby><cites>FETCH-LOGICAL-c455t-af13007aff61bcc4436320179090c3b00fcdd87bcbfe003a34e158fa5ffac953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362720/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362720/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1756156$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10188896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cintin, C</creatorcontrib><creatorcontrib>Johansen, J S</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Price, P A</creatorcontrib><creatorcontrib>Sørensen, S</creatorcontrib><creatorcontrib>Nielsen, H J</creatorcontrib><title>Serum YKL-40 and colorectal cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Summary
YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes’ A, 26% with Dukes’ B, 19% with Dukes’ C and 39% with Dukes’ D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (
P
< 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1,
P
< 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes’ stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8,
P
= 0.007). These results suggest that YKL-40 may play an important role in tumour invasion.</description><subject>Adipokines</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Case-Control Studies</subject><subject>Chitinase-3-Like Protein 1</subject><subject>Colonic Neoplasms - blood</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - pathology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Glycoproteins - blood</subject><subject>Humans</subject><subject>Lectins</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Rectal Neoplasms - blood</subject><subject>Rectal Neoplasms - mortality</subject><subject>Rectal Neoplasms - pathology</subject><subject>Regular</subject><subject>regular-article</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1kM1LwzAYh4Mobk6vHmWIeGv3pmnS9CLI8AsHHtzFU0jTZLb0Yyat4H9vRovOg6cQ3uf9_V4ehM4xhBgIX7gyzEoVMpZCRPgBmmJKogDzKDlEUwBIAkgjmKAT50r_TYEnx2iCAXPOUzZFl6_a9vX87XkVxDCXTT5XbdVarTpZzZVslLan6MjIyumz8Z2h9f3devkYrF4enpa3q0DFlHaBNJj4PmkMw5lScUwYiQAnqS9VJAMwKs95kqnMaAAiSawx5UZSY6RKKZmhmyF222e1zpVuOisrsbVFLe2XaGUh_k6a4l1s2k8RERYlEfiA6zHAth-9dp2oC6d0VclGt70TLGXMX4g9GA6gsq1zVpufEgxiZ1W4UnirYrTqFy72T9vDB40euBoB6ZSsjPXiCvfLJZRhusMWA-b8pNloK8q2t42X-l_zN54Xj5I</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Cintin, C</creator><creator>Johansen, J S</creator><creator>Christensen, I J</creator><creator>Price, P A</creator><creator>Sørensen, S</creator><creator>Nielsen, H J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990301</creationdate><title>Serum YKL-40 and colorectal cancer</title><author>Cintin, C ; Johansen, J S ; Christensen, I J ; Price, P A ; Sørensen, S ; Nielsen, H J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-af13007aff61bcc4436320179090c3b00fcdd87bcbfe003a34e158fa5ffac953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adipokines</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Case-Control Studies</topic><topic>Chitinase-3-Like Protein 1</topic><topic>Colonic Neoplasms - blood</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - pathology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Glycoproteins - blood</topic><topic>Humans</topic><topic>Lectins</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Rectal Neoplasms - blood</topic><topic>Rectal Neoplasms - mortality</topic><topic>Rectal Neoplasms - pathology</topic><topic>Regular</topic><topic>regular-article</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cintin, C</creatorcontrib><creatorcontrib>Johansen, J S</creatorcontrib><creatorcontrib>Christensen, I J</creatorcontrib><creatorcontrib>Price, P A</creatorcontrib><creatorcontrib>Sørensen, S</creatorcontrib><creatorcontrib>Nielsen, H J</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cintin, C</au><au>Johansen, J S</au><au>Christensen, I J</au><au>Price, P A</au><au>Sørensen, S</au><au>Nielsen, H J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum YKL-40 and colorectal cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>1999-03-01</date><risdate>1999</risdate><volume>79</volume><issue>9</issue><spage>1494</spage><epage>1499</epage><pages>1494-1499</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Summary
YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes’ A, 26% with Dukes’ B, 19% with Dukes’ C and 39% with Dukes’ D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (
P
< 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3–2.1,
P
< 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes’ stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1–1.8,
P
= 0.007). These results suggest that YKL-40 may play an important role in tumour invasion.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>10188896</pmid><doi>10.1038/sj.bjc.6690238</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1999-03, Vol.79 (9), p.1494-1499 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2362720 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adipokines Adult Aged Aged, 80 and over Analysis of Variance Biological and medical sciences Biomarkers, Tumor - blood Biomedical and Life Sciences Biomedicine Cancer Research Carcinoembryonic Antigen - blood Case-Control Studies Chitinase-3-Like Protein 1 Colonic Neoplasms - blood Colonic Neoplasms - mortality Colonic Neoplasms - pathology Drug Resistance Epidemiology Female Gastroenterology. Liver. Pancreas. Abdomen Glycoproteins - blood Humans Lectins Male Medical sciences Middle Aged Molecular Medicine Neoplasm Staging Oncology Rectal Neoplasms - blood Rectal Neoplasms - mortality Rectal Neoplasms - pathology Regular regular-article Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Analysis Tumors |
| title | Serum YKL-40 and colorectal cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T20%3A11%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20YKL-40%20and%20colorectal%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Cintin,%20C&rft.date=1999-03-01&rft.volume=79&rft.issue=9&rft.spage=1494&rft.epage=1499&rft.pages=1494-1499&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/sj.bjc.6690238&rft_dat=%3Cproquest_pubme%3E69663001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69663001&rft_id=info:pmid/10188896&rfr_iscdi=true |